Showing 1,081 - 1,100 results of 1,132 for search '"immunosuppression"', query time: 0.06s Refine Results
  1. 1081

    Adipose Tissue-Derived Stromal Cells Induce a Highly Trophic Environment While Reducing Maturation of Monocyte-Derived Dendritic Cells by Morten Juhl, Bjarke Follin, Monika Gad, Jesper Larsen, Jens Kastrup, Annette Ekblond

    Published 2020-01-01
    “…Dexamethasone was included as an immunosuppressive control. Dendritic cells were analyzed by flow cytometry for CD11c, CD40, CD80, CD83, CD86, PD-L1, and HLA-DR, and supernatants were analyzed for FGF2, HGF, IL-10, IL-12p70, LIF, MIF, PDGF, PlGF, and IDO. …”
    Get full text
    Article
  2. 1082

    HLA-DMB correlates with antitumor immunity and an improved prognosis in endometrial carcinoma tumors by Xiaoyu Xi, Xiaona Zhang, Jianxin Tang, Xiumei Fan, Jiexian Du

    Published 2025-01-01
    “…Furthermore, TISIDB was utilized to predict the relationships between HLA-DMB and various immune enhancement factors as well as immunosuppressive factors. Gene Ontology (GO) analysis and Gene Set Enrichment Analysis (GSEA) were employed to explore the signaling pathways associated with HLA-DMB in endometrial cancer. …”
    Get full text
    Article
  3. 1083

    Renal Dysfunction after Living-Donor Liver Transplantation: Experience with 500 Cases by Ehab E. Abdel-Khalek, Alrefaey K. Alrefaey, Amr M. Yassen, Ahmed Monier, Hesham M. Elgouhari, Mohamed Samy Habl, Gehad Tawfik, Thuraya Elzayat, Reham Adly Zayed, Mohamed Abdel-Wahab

    Published 2018-01-01
    “…A calcineurin inhibitor-based immunosuppressive regimen, either tacrolimus or cyclosporine, was used in all the patients. …”
    Get full text
    Article
  4. 1084

    Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile by Manuel Weber, Falk Wehrhan, Christoph Baran, Abbas Agaimy, Maike Büttner‐Herold, Marco Kesting, Jutta Ries

    Published 2019-03-01
    “…Local PD‐L2 expression in tissue samples might be useful as a diagnostic parameter for malignancy and could contribute to the immunosuppressive local microenvironment in OSCC.…”
    Get full text
    Article
  5. 1085

    Fatal toxoplasmic encephalitis triggered by anti-TNF therapy by Rodrigo A. Montoro, Michael Moran, Katherine A. Overmyer, Andrew Periaccante, Joshua J. Coon, Swapnil Lanjewar, Laura J. Knoll, Rob Striker

    Published 2025-02-01
    “…T. gondii reactivation cases have been strongly associated with acquired immunodeficiency syndrome, but other immunosuppressive situations are also associated. Anti-TNF-α therapy reliably triggers the reactivation of T. gondii latent cysts in mice models. …”
    Get full text
    Article
  6. 1086
  7. 1087

    Systemic disease activity measured with ESSDAI varies largely over 5 years in a prospective, longitudinal cohort of patients with Sjögren’s disease by Suzanne Arends, Arjan Vissink, Hendrika Bootsma, Liseth de Wolff, Gwenny Verstappen, Alja Stel, Greetje van Zuiden, Jolien van Nimwegen, Frans Kroese

    Published 2025-01-01
    “…Patient-reported, objective glandular and laboratory outcomes were compared between patients with ESSDAI LDA (score<5) for <75% vs ≥75% of time.Results Of 265 included patients with SjD, 236 (89%) were women, median disease duration was 6 years (IQR 2–10) and 114 (43%) received immunosuppressive treatment at some point during follow-up. …”
    Get full text
    Article
  8. 1088

    The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure by Shaoxue Ding, Xiaowei Liang, Tian Zhang, Rong Fu

    Published 2020-01-01
    “…Most patients with AA respond to immunosuppressive therapy (IST), usually as antithymocyte globulin (ATG) and cyclosporine (CsA), but some relapse on CsA withdrawal or require long-term administration of CsA to maintain blood counts. …”
    Get full text
    Article
  9. 1089

    A multi-stakeholder collaborative approach to awareness, education and support needed in the haemophilia gene therapy patient journey – a report on insights from a European patient... by O’Mahony Brian, Fletcher Simon, Baarslag Manuel, Khair Kate, Breederveld Daan, Jansen Nathalie, Pembroke Luke, Pinachyan Karen, Sivasubramaniyam Sujan

    Published 2024-04-01
    “…Other key educational needs included follow-up commitments, the role and potential side effects of corticosteroids or other immunosuppressants, impact on sense of identity, mental health, family planning, and managing bleeds after gene therapy. …”
    Get full text
    Article
  10. 1090

    Human cytomegalovirus (HCMV) trends in Sri Lanka: insights from a hospital-based seroprevalence analysis by Narapity Pathirannehalage Sunil-Chandra, Madawala Vithanage Madusha Lakmali Jayasundara, Maththe Gama Ralalage Shobha Sanjeewani Gunathilaka, Suduwa Dewage Himal Suminda

    Published 2025-02-01
    “…Latent HCMV may reactivate in immunosuppressed individuals. This study aimed to determine the age and gender specific seroprevalence of HCMV in selected populations in Sri Lanka. …”
    Get full text
    Article
  11. 1091

    Conventional type 1 dendritic cells in the lymph nodes aggravate neuroinflammation after spinal cord injury by promoting CD8+ T cell expansion by Li-Qing Wang, Xiao-Yi Wang, Yue-Hui Ma, Heng-Jun Zhou

    Published 2025-02-01
    “…In vivo, the fms-like tyrosine kinase 3 (Flt3) inhibitor quizartinib was administered to deplete cDC1s, while intraperitoneal injection of recombinant Flt3L and immunosuppressive drug FTY-720 was used to expand cDC1s and prevent T cell egress from lymph nodes (LNs), respectively. …”
    Get full text
    Article
  12. 1092

    Inflammatory adhesion mediates myocardial segmental necroptosis induced by mixed lineage kinase domain-like protein in acute myocardial infarction by Lijiang Wei, Naifu Wan, Wentong Zhu, Chenchen Liu, Zeyu Chen, Wuwei Rong, Lujun Zhang, Meifeng Xie, Yueqi Qin, Ting Sun, Qing Jing, Ankang Lyu

    Published 2025-01-01
    “…In a mouse model of AMI, we observed MSN, which was absent in immunosuppressed mice. Pharmacological depletion of macrophages or genetic knockout of macrophage-specific MLKL (MLKLM−KO) reduced the occurrence of MSN. …”
    Get full text
    Article
  13. 1093

    Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protoc... by Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present

    Published 2025-02-01
    “…Patients with Behçet’s disease (BD), idiopathic inflammatory myopathies (IIM) and IgG4-related disease (IgG4-RD) typically undergo treatment involving prolonged administration of high-dose glucocorticoids and immunosuppressants. Both are associated with an increased risk of infection. …”
    Get full text
    Article
  14. 1094

    Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease by Linda Mastromanno, Federico Giardina, Angelica Gattamelata, Serena Colafrancesco, Simona Truglia, Francesca Romana Spinelli, Edoardo Simoncelli, Bruno Lucchino, Fabrizio Conti, Roberta Priori

    Published 2025-01-01
    “…Among the patient’s cohort, 60% contracted SARS-CoV-2 infection, and 41.67% were on immunosuppressants at the time of the infection. One patient presented with severe COVID-19. …”
    Get full text
    Article
  15. 1095

    Early sST2 Liberation after Implantation of a Left Ventricular Assist Device in Patients with Advanced Heart Failure by Philipp Opfermann, Elisabeth Simader, Alessia Felli, Michele Bevilacqua, Caroline Holaubek, Martin Dworschak, Mohamed Mouhieddine, Daniel Zimpfer, Jan Hendrik Ankersmit, Barbara Steinlechner

    Published 2020-01-01
    “…We examined the early expression of circulating soluble ST2 (sST2), a biomarker with immunosuppressive and profibrotic activity, and assessed the risk of death at 1 year in patients receiving LVAD implant. …”
    Get full text
    Article
  16. 1096

    Mesenchymal Stem Cells Carrying Viral Fusogenic Protein p14 to Treat Solid Tumors by Inducing Cell–Cell Fusion and Immune Activation by Yao Wang, Xunlei Pang, Ruirui Li, Jiuzhou Chen, Chen Wen, Huihuang Zhu, Tingyu Long, Jianjie Li, Lijun Zheng, Youcai Deng, Junnian Zheng, Bo Xu

    Published 2025-01-01
    “…This limitation may contribute to their inefficiency in treating solid tumors, given the restricted intratumoral infiltration and immunosuppressive tumor microenvironment. Therefore, cell–cell fusion as a cell-killing mechanism might develop a novel cytotherapy aimed at improving the efficacy against solid tumors. …”
    Get full text
    Article
  17. 1097

    Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9 by Tao Fan, Chu Xiao, Ziqin Deng, Shuofeng Li, He Tian, Yujia Zheng, Bo Zheng, Chunxiang Li, Jie He

    Published 2025-01-01
    “…Importantly, this risk-score system showed satisfactory predictive performance for the ICB therapy responses of patients suffering from several cancer types, and we identified that SLAMF9 was one of the immunosuppressive phenotype and immunotherapy resistance-determined genes of H3K4me3-RS. …”
    Get full text
    Article
  18. 1098

    PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database by Alexandre O. Gérard, Alexandre O. Gérard, Alexandre O. Gérard, Diane Merino, Diane Merino, Jonathan Benzaquen, Alexandre Destere, Delphine Borchiellini, Clément Gosset, Clément Gosset, Fanny Rocher, Marine Andreani, Charles-Hugo Marquette, Henri Montaudié, Henri Montaudié, Milou-Daniel Drici, Antoine Sicard, Antoine Sicard

    Published 2025-01-01
    “…BackgroundTransplant recipients face increased cancer mortality due to immunosuppressive treatments. Immune checkpoint inhibitors (ICI) have improved survival rates, but data on the use of these agents in transplant recipients is scarce. …”
    Get full text
    Article
  19. 1099

    Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer by Lulu Zhang, Lulu Zhang, Xiyuan Guo, Xiyuan Guo, Xiaoke Sun, Jue Liao, Qin Liu, Yingchun Ye, Zhihui Yang, Ratchada Cressey, Qing He, Qing Yuan, Qing Yuan

    Published 2025-02-01
    “…ObjectiveGiven the limitations of immunotherapy for treating non-small cell lung cancer (NSCLC), we investigated the phenotype and function of exhausted CD8+T cells and analyzed a novel combination immunotherapy to restore the effector killing function of tumor-infiltrating CD8+T lymphocyte (TIL).MethodsWe examined the expression and function of immunosuppressive molecules on CD8+T cells of peripheral blood mononuclear cells (PBMCs) and TILs by using prospectively collected peripheral blood, pleural effusions, and tumor tissues from patients with NSCLC and correlated the results with clinical data. …”
    Get full text
    Article
  20. 1100

    Association of HIV infection and hospitalization among mpox cases: a systematic review and meta-analysis by Muhammed Shabil, Shilpa Gaidhane, R. Roopashree, Mandeep Kaur, Manish Srivastava, Amit Barwal, G. V. Siva Prasad, Pranchal Rajput, Rukshar Syed, Anoop Dev, Danish Kundra, Ambanna Yappalparvi, Prakasini Satapathy, Quazi Syed Zahiruddin, Harish Kumar, Renu Sah, Ganesh Bushi

    Published 2025-01-01
    “…The relationship between human immunodeficiency virus (HIV) infection and mpox outcomes, particularly hospitalization rates, remains underexplored despite the known immunosuppressive effects of HIV. This systematic review and meta-analysis aimed to clarify the association between HIV infection and the likelihood of hospitalization in mpox cases. …”
    Get full text
    Article